These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 31244990)

  • 1. Current options and future possibilities for the systemic treatment of hepatocellular carcinoma.
    Raoul JL; Frenel JS; Raimbourg J; Gilabert M
    Hepat Oncol; 2019 Jun; 6(1):HEP11. PubMed ID: 31244990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current treatment options for hepatocellular carcinoma.
    Eugen K
    Klin Onkol; 2020; 33(Supplementum 3):20-25. PubMed ID: 33213161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review article: systemic treatment of hepatocellular carcinoma.
    Pinter M; Peck-Radosavljevic M
    Aliment Pharmacol Ther; 2018 Sep; 48(6):598-609. PubMed ID: 30039640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of immunotherapy in the management of hepatocellular carcinoma: current standards and future directions.
    Weinmann A; Galle PR
    Curr Oncol; 2020 Nov; 27(Suppl 3):S152-S164. PubMed ID: 33343209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic targeted and immunotherapy for advanced hepatocellular carcinoma.
    Cersosimo RJ
    Am J Health Syst Pharm; 2021 Jan; 78(3):187-202. PubMed ID: 33211092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
    Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
    Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic Treatment for Advanced Hepatocellular Carcinoma.
    Bouattour M; Mehta N; He AR; Cohen EI; Nault JC
    Liver Cancer; 2019 Oct; 8(5):341-358. PubMed ID: 31768344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma.
    Trojan J; Waidmann O
    J Hepatocell Carcinoma; 2016; 3():31-36. PubMed ID: 27703962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic therapies for hepatocellular carcinoma: the present and the future.
    Celsa C; Giuffrida P; Stornello C; Grova M; Spatola F; Rizzo GEM; Busacca A; Cannella R; Battaglia S; Cammà C; Cabibbo G
    Recenti Prog Med; 2021 Feb; 112(2):110-116. PubMed ID: 33624623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic Treatment Options in Hepatocellular Carcinoma.
    Rimassa L; Pressiani T; Merle P
    Liver Cancer; 2019 Nov; 8(6):427-446. PubMed ID: 31799201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular therapies for HCC: Looking outside the box.
    Faivre S; Rimassa L; Finn RS
    J Hepatol; 2020 Feb; 72(2):342-352. PubMed ID: 31954496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Navigating the new landscape of second-line treatment in advanced hepatocellular carcinoma.
    Rimassa L; Wörns MA
    Liver Int; 2020 Aug; 40(8):1800-1811. PubMed ID: 32432830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic therapy for advanced hepatocellular carcinoma: targeted therapies.
    Tella SH; Kommalapati A; Mahipal A
    Chin Clin Oncol; 2021 Feb; 10(1):10. PubMed ID: 32434345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapy or immunotherapy? Optimal treatment in hepatocellular carcinoma.
    Contratto M; Wu J
    World J Gastrointest Oncol; 2018 May; 10(5):108-114. PubMed ID: 29770170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review article: new therapeutic interventions for advanced hepatocellular carcinoma.
    Bangaru S; Marrero JA; Singal AG
    Aliment Pharmacol Ther; 2020 Jan; 51(1):78-89. PubMed ID: 31747082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update.
    Kudo M
    Liver Cancer; 2020 Dec; 9(6):640-662. PubMed ID: 33442538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond.
    Raoul JL; Kudo M; Finn RS; Edeline J; Reig M; Galle PR
    Cancer Treat Rev; 2018 Jul; 68():16-24. PubMed ID: 29783126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Changing Landscape of Systemic Treatment of Advanced Hepatocellular Carcinoma: New Targeted Agents and Immunotherapies.
    Marquardt JU; Saborowski A; Czauderna C; Vogel A
    Target Oncol; 2019 Apr; 14(2):115-123. PubMed ID: 30805831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis.
    Sonbol MB; Riaz IB; Naqvi SAA; Almquist DR; Mina S; Almasri J; Shah S; Almader-Douglas D; Uson Junior PLS; Mahipal A; Ma WW; Jin Z; Mody K; Starr J; Borad MJ; Ahn DH; Murad MH; Bekaii-Saab T
    JAMA Oncol; 2020 Dec; 6(12):e204930. PubMed ID: 33090186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab.
    Fung AS; Tam VC; Meyers DE; Sim HW; Knox JJ; Zaborska V; Davies J; Ko YJ; Batuyong E; Samawi H; Cheung WY; Lee-Ying R
    Cancer Med; 2020 Jul; 9(13):4640-4647. PubMed ID: 32378799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.